Evidence map›Paper›PMID 31782573›Full record

ArticleMolecular carcinogenesis2020

Gartanin is a novel NEDDylation inhibitor for induction of Skp2 degradation, FBXW2 expression, and autophagy.

Victor Pham, Raymond Rendon, Vinh X Le, Matthew Tippin, Dong-Jun Fu, Thanh H Le, Marvin Miller, Ericka Agredano, Jose Cedano, Xiaolin Zi

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular carcinogenesis, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 30 citations in OpenAlex.

  1. Review
  2. Review
  3. Inhibiting neddylation: A new strategy for tumor therapy.Journal of pharmaceutical analysis · 2025
    Review
  4. Review
  5. Article
  6. Protein neddylation and its role in health and diseases.Signal transduction and targeted therapy · 2024
    Review
  7. Review
  8. Article
  9. Discovery of dual tubulin-NEDDylation inhibitors with antiproliferative activity.Journal of enzyme inhibition and medicinal chemistry · 2023
    Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Victor PhamDepartment of Urology, University of California, Irvine, California.
Raymond RendonDepartment of Urology, University of California, Irvine, California.
Vinh X LeDepartment of Urology, University of California, Irvine, California.
Matthew TippinDepartment of Urology, University of California, Irvine, California.
Dong-Jun FuDepartment of Urology, University of California, Irvine, California.
Thanh H LeDepartment of Urology, University of California, Irvine, California.
Marvin MillerDepartment of Urology, University of California, Irvine, California.
Ericka AgredanoDepartment of Urology, University of California, Irvine, California.
Jose CedanoDepartment of Urology, University of California, Irvine, California.
Xiaolin ZiDepartment of Urology, University of California, Irvine, California.ORCID 0000-0002-5312-7158
University of California, Irvine · US

Funding

The NEDD8 pathway mediated Skp2 degradation in chemoprevention by FKAR01CA193967 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI ZI, XIAOLIN · 2016 to 2020
$1.8M
Rhodiola Rosea Extracts, Salidroside and Bladder Cancer ChemopreventionR21CA152804 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI ZI, XIAOLIN · 2011 to 2012
$366k
NCI NIH HHS R01 CA193967NCI NIH HHS R21 CA152804
6 · The paper itself

Abstract

Gartanin, a 4-prenylated xanthone, has been identified from the purple mangosteen fruit as a potent growth inhibitor of various cancer cell lines, including prostate cancer. However, much of Gartanin's anticancer mechanism remains unknown. We have discovered that Gartanin docked onto the regulatory subunit of the precursor cell-expressed developmentally downregulated 8 (NEDD8)-activating enzyme (NAE) complex and next to the NEDD8 binding complex, which leads to inhibit NEDD8 conjugations to both Cullin1 and Ubc12 in prostate cancer cell lines and Ubc12 NEDDylation in an in vitro assay. The S phase kinase-associated protein (Skp2) and F-box and WD-repeat domain-containing 2 (FBXW2), the NEDD8 family members of E3 ubiqutin ligases, were also downregulated and upregulated by Gartainin, respectively. Knock-down of NEDD8 expression by short harpin (Sh) RNAs blocked or attenuated these effects of Gartainin. Finally, Gartanin demonstrated its ability to inhibit growth of prostate cancer lines via autophagy initiation. Our data support that Gartanin is a naturally occurring NEDDylation inhibitor and deserves further investigation for prostate cancer prevention and treatment.

Indexed as

ApoptosisAutophagyCell Line, TumorCell ProliferationCell SurvivalDose-Response Relationship, DrugF-Box ProteinsHumansMaleNEDD8 ProteinPC-3 CellsProstatic NeoplasmsRNA InterferenceS-Phase Kinase-Associated ProteinsXanthones1,3,5,8-tetrahydroxy-2,4-bis(3-methyl-2-butenyl)xanthoneF-Box ProteinsFBXW2 protein, humanNEDD8 ProteinNEDD8 protein, humanSKP2 protein, humanS-Phase Kinase-Associated ProteinsXanthoneschemopreventionGartaninneddylationprostate cancerSkp2

Identifiers

PMID31782573
PMCPMC6946862
OpenAlexW2990409302

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.